Fundamental Analysis (FA)
Framework: DCF Benchmarked
Join Palmy To Bypass The Blur →
For GSK.L
Valuation Somewhat Weak
43%
Profitability n.A.
Fin. Growth Positive
67%
Leverage & Liquidity Weak
17%
Per Share Metrics Bad
0%
Fin. Health n.A.
Fundamental Analysis (FA)
Benchmarked
1 Financial Health
Metric Q4 Q1 Δ in %
Current Ratio -2.04 0.87 0.88
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -12.51 5.92 6.76
Naive Interpretation member
2 Per Share
Metric Q4 Q1 Δ in %
Book Value 3.37 3.40 3.29
Cash -21.22 1.01 1.28
Capex 28.32 -0.14 -0.19
Free Cash Flow -82.87 0.09 0.54
Revenue -8.84 1.81 1.99
Naive Interpretation member
3 Profitability
Metric Q4 Q1 Δ in %
Gross Margin 3.85 0.74 0.71
Operating Margin 106.14 0.27 0.13
ROA 201.38 0.02 < 0.005
ROE 188.21 0.08 0.03
ROIC 37.37 0.05 0.04
Naive Interpretation member
4 Valuation
The "Valuation Entry" for the Focus of GSK.L is permitted for members.
5 Growth
The "Growth Entry" for the Focus of GSK.L is permitted for members.
6 Leverage & Liquidity
The "Leverage & Liquidity Entry" for the Focus of GSK.L is permitted for members.